Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03759288 · ClinicalTrials.gov registry record · Phase 2
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT03759288 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 89 participants.
The verdict
NCT03759288, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy
Interventions
- DRUG Placebo
- DRUG Humira®
- DRUG Brazikumab low dose
- DRUG Brazikumab high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03759288
The ClinicalTrials.gov registry entry for NCT03759288 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03759288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03759288 about?
NCT03759288 is a clinical study titled "An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease". This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal...
What is the current status of trial NCT03759288?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2018-12-07. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT03759288?
The interventions under investigation include: Placebo (DRUG), Humira® (DRUG), Brazikumab low dose (DRUG), Brazikumab high dose (DRUG).
Who is sponsoring clinical trial NCT03759288?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.